Gluctam (Gliclazide)

Gluctam is prescribed for the management of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient. It is used as part of a comprehensive diabetes care plan that may include lifestyle modification and regular monitoring of blood glucose.

• Improves glycemic control in adults with type 2 diabetes.
• Can be combined with metformin or other oral antidiabetic agents.
• May be used when insulin therapy is not yet required.
• Supports long‑term reduction of fasting and post‑prandial glucose levels.
• Often considered after lifestyle measures have not achieved target glucose values.

Side effects of Gluctam vary in frequency and severity. Patients should be aware of both common and potentially serious reactions.

Common

• Mild hypoglycemia, especially if meals are missed.
• Gastrointestinal upset such as nausea or abdominal discomfort.
• Headache or dizziness.
• Skin rash or mild itching.
• Weight gain due to improved glucose utilization.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions including swelling of face, lips, or tongue.
• Hepatic dysfunction indicated by abnormal liver enzymes.
• Hematologic abnormalities such as leukopenia or thrombocytopenia.
• Persistent gastrointestinal bleeding.

Before starting Gluctam, certain health considerations should be reviewed to ensure safe use.

• Assess renal and hepatic function; dose adjustments may be needed.
• Use cautiously in elderly patients due to increased hypoglycemia risk.
• Avoid in patients with known sulfonylurea hypersensitivity.
• Monitor blood glucose regularly, especially during dose changes.
• Pregnancy category B: discuss risks and benefits with a healthcare provider.
• Breastfeeding mothers should consult a physician before use.
• Discontinue if severe hypoglycemia or allergic reaction occurs.

Gluctam may interact with several drug classes, affecting its efficacy or safety profile.

Avoid

• Other sulfonylureas or insulin products, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may increase gliclazide levels.
• MAO‑B inhibitors, which can potentiate hypoglycemic effects.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask hypoglycemia symptoms.
• Beta‑blockers, which can blunt typical hypoglycemia warning signs.
• Thiazide diuretics, as they may affect glucose metabolism.
• Antidepressants such as SSRIs, which have been reported to alter glycemic control.